Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.

about

Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.

Item

http://www.wikidata.org/entity/Q44389468

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Aviscumine, a recombinant ribo ...... ivity of natural killer cells.

@en

Aviscumine, a recombinant ribo ...... ivity of natural killer cells.

@nl

type

Item

label

Aviscumine, a recombinant ribo ...... ivity of natural killer cells.

@en

Aviscumine, a recombinant ribo ...... ivity of natural killer cells.

@nl

prefLabel

Aviscumine, a recombinant ribo ...... ivity of natural killer cells.

@en

Aviscumine, a recombinant ribo ...... ivity of natural killer cells.

@nl

P1476

Aviscumine, a recombinant ribo ...... ivity of natural killer cells.

@en

P2093

Arno Amann

http://www.w3.org/2001/XMLSchema#string

Bettina Schenk

http://www.w3.org/2001/XMLSchema#string

Dirk O Mügge

http://www.w3.org/2001/XMLSchema#string

Gabriele Gamerith

http://www.w3.org/2001/XMLSchema#string

Hans Lentzen

http://www.w3.org/2001/XMLSchema#string

Heinz Zwierzina

http://www.w3.org/2001/XMLSchema#string

Judith Löffler-Ragg

http://www.w3.org/2001/XMLSchema#string

Katharina M Cima

http://www.w3.org/2001/XMLSchema#string

Thomas Auer

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hilbe

http://www.w3.org/2001/XMLSchema#string

P2860

Immune Checkpoint Blockade in Cancer Therapy

Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.

"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.

Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study.

NK cell-based immunotherapies in Pediatric Oncology.

P304

5563-5568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.6861

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29142605

http://www.w3.org/2001/XMLSchema#string

P932

5666656

http://www.w3.org/2001/XMLSchema#string